Growth Opportunities in the HIV Rapid Test Kits Market, 2025-2030 - HIV Self-Testing Policies Propel Market Growth as Global Vendors Compete for Dominance - ResearchAndMarkets.com

The "HIV Rapid Test Kits Market - Focused Insights 2025-2030" report has been added to ResearchAndMarkets.com's offering.

The HIV Rapid Test Kits Market was valued at USD 1.49 billion in 2024, and is projected to reach USD 1.82 billion by 2030, rising at a CAGR of 3.39%.

North America dominates and holds the largest global HIV rapid test kits market share of over 30%. The North American market is one of the largest and most mature markets for HIV rapid test kits. The region has witnessed more than 1.3 million HIV cases and significant adoption of HIVST policies. The high acceptance of HIV rapid test kits and their associated cost-effectiveness account for the highest revenue growth. Furthermore, North America is home to several small, medium, and large market players who widely promote HIVST policies to combat HIV infection across the region. In North America, both the US and Canada are supporting HIVST policies, which fuel the demand for HIV rapid test kits. Since 2022, both countries have reported an increasing number of HIV cases compared to previous years. The implementation of HIVST policies is expected to further increase HIV testing volumes in the region.

The Europe HIV rapid test kits market shows prominent growth, with the highest CAGR of 5.90% during the forecast period. This growth is primarily driven by Eastern Europe, where the increasing prevalence of HIV and the rising acceptance and implementation of HIVST policies are key factors. In Europe, some countries - including Montenegro, Malta, Ireland, Lithuania, Iceland, Azerbaijan, and Finland - recorded the highest number of HIV diagnoses in a single year in 2023, compared to the past decade. The rapidly growing acceptance of HIVST policies, the rising prevalence of HIV infections, and the presence of high-risk populations are some of the leading factors accelerating market growth in Europe.

The global HIV rapid test kits market report consists of exclusive data on 27 vendors. The market is characterized by diversified market players and high competition among players. The current market scenario is driving vendors to innovate and refine their unique value propositions to achieve a strong market presence. However, the market is also susceptible to the threat of infiltration by low-quality products. Major vendors in the market continually compete for leadership, with occasional surges of competition from local players.

Abbott, Bio-Rad Laboratories, and BIOMERIEUX are three leading companies that account for the highest market share in the global HIV rapid test kits market. These vendors offer high-quality and reliable HIV rapid test kits that meet customer requirements and international regulations, while also improving product efficiency to strengthen their market position. These companies have strong brand recognition and a wide geographical reach across the global market. Additionally, strategies such as product launches and new product development with advanced technologies have intensified competition. The adoption of these strategies by major market players, along with their focus on expanding capabilities, has enabled them to capture a larger revenue share in the market. Furthermore, BIOSYNEX and OraSure Technologies are identified as rapidly growing vendors in the market.

MARKET TRENDS & DRIVERS

Number of Countries Adopting HIV Self-Testing Policies Rises Sharply

The World Health Organization (WHO) and Unitaid- a healthcare organization that supports and promotes HIVST reported that several countries recently adopted HIVST strategies. Compared to the previous decade, Unitaid reported the growing number of HIVST products entering the market along with an increase in the number of countries adopting HIVST. Since 2016, around 40 countries adopted HIVST strategies that led to increase the adoption of HIV rapid test kits. In addition, the COVID-19 pandemic positively influenced the adoption of a rapid test kit use approach in infectious disease management. Based on that, an additional 48 countries have recently developed national HIV self-testing policies.

Introduction of Next-Generation HIV Rapid Test Kits

HIV rapid test kits have evolved into advanced forms of testing. The application of fourth-generation and fifth-generation rapid test kits is currently high in the market and is expected to become popular in upcoming years. This technology is more accurate and reliable for screening the acute HIV presence from samples. Fourth-generation HIV test kits easily detect HIV in less time and more accurately than other-generation technologies. This allows individuals to detect and treat sooner and potentially prevent the spread of infection to others. 5th Generation HIV rapid test kits are used to distinguish between HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen. These newly developed solutions offer more information about HIV status.

Rising Promotion of HIVST With Pre-Exposure Prophylaxis Delivery Integration

Self-testing is an early and widely adopted strategy worldwide in the HIV response and has since changed service delivery across many disease areas and conditions. While it was initially targeted to enable early diagnosis now it shifts to the prevent new infections. This new HIV preventive approach has led to the integration of HIVST policies with Pre-exposure prophylaxis (PrEP) delivery. PrEP is the application of antiretroviral medication by HIV-negative people to reduce the risk of HIV acquisition. For achievement of the first 95 targets, further growth in the HIV rapid test kits market is only expected when countries expand PrEP delivery and or with the uptake of HIVST. The first 95 target is one of the major approaches considered across the world to increase awareness, acceptance, and delivery of HIV diagnosis.

Government Initiatives and Investment

To improve the HIV status, globally several government initiatives were taken in recent years. These initiatives and associated investments aim to overcome the challenges associated with HIV testing and account for cost as well as increase access to HIV testing. Of these, some major initiatives are STAR Phase 3, ATLAS, and MTV Shuga. STAR initiative was started in 2005 to improve and increase the adoption of HIV self-testing in targeted countries. Now its Star Phase 3 part is supporting to increase acceptance of HIV self-testing in new 7 countries. It involves a further seven markets, including Mozambique, Cameroon, Tanzania, Nigeria, Uganda in Africa; and Indonesia and India in Asia. In these countries, the Star Phase 3 initiative invested around $16.9 million to establish the system, structure, and oversight mechanism essential for the long-term sustainability of HIVST, reported in 2021.

KEY TAKEAWAYS

• By Technology: The lateral flow immunoassay segment holds the largest market share. Ease of use and low cost are major factors that increase acceptance of lateral flow immunoassay technology in HIV rapid test kits.
• By Sample Type: The oral-fluid sample segment shows the highest growth of 4.02%. The oral-fluid test has received support from public health officials and activists as it can increase the testing rate and awareness of HIV serostatus.
• By Gender: In 2024, the women segment holds the largest market share as HIV is highly prevalent among women compared to men.
• By Distribution Channel: The offline segment accounts for the largest market share. Offline distribution channels are the first point of resource for HIV testing. Most people choose medical pharmacies as the first care point to purchase HIV rapid test kits.
• By Geography: North America dominates and holds the largest market share of over 30%. The market is growing due to to increasing prevalence of HIV and associated growing awareness about HIVST.
• Growth Factor: The global HIV rapid test kits market is set to grow due to the rising promotion of HIVST with pre-exposure prophylaxis delivery integration and increasing government investments and initiatives.

Key Vendors

• Abbott
• Bio-Rad Laboratories
• BIOMERIEUX
• Biosynex SA
• OraSure Technologies

Other Prominent Vendors

• Alpine Biomedicals
• AdvaCare Pharma
• Atomo Diagnostics
• AccuBioTech
• bioLytical Laboratories
• Cupid Limited
• HUMAN
• INTEC
• J. Mitra & Co. Pvt. Ltd.
• Meril Life Sciences
• MP BIOMEDICALS
• Medsource Ozone Biomedicals
• Nanjing Synthgene Medical Technology
• Premier Medical
• SD Biosensor
• Shanghai Kehua Biotech - KHB
• Revital Healthcare
• Tulip Diagnostics
• Trinity Biotech
• Turklab A.S.
• Wantai BioPharma
• Wondfo

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/rmvapb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319182346/en/